Impact of USAID and PEPFAR funding cuts on global HIV clinics
HumanitarianComments
The scale-up is a valid point, but I wonder about the specific regulatory frameworks in place. Do these new regional hubs have the capacity for the rigorous stability testing required to ensure long term ART (antiretroviral therapy) efficacy?
The vaccine rollout showed that 'local capacity' is often a buzzword until the first failed batch. Regulatory alignment usually lags far behind the actual construction of the factories.
I'm skeptical about the 'dozens of countries' figure. Usually, these facilities merge into larger district hospitals to save overhead rather than shutting down entirely.
If we view this through the lens of the current administration's move toward bilateralism, this could be a push for host nations to internalize costs. Is it possible this is less about a retreat and more about a forced transition to national sovereignty over health?
That transition to national sovereignty could actually accelerate the growth of regional pharmaceutical hubs. Some countries in East Africa are already scaling up generic production, which might provide a more sustainable long term solution.
The core issue is the procurement volume. Losing PEPFAR's bulk purchasing power spikes the cost of antiretrovirals for every remaining clinic, regardless of whether the physical building stays open.